Dipna Pharmachem Limited has issued a clarification to BSE Limited regarding significant movement in its stock price, stating that no material information exists within the company that could have caused such fluctuations. The response, dated January 21, 2026, addresses BSE's inquiry letter received on January 13, 2026.

Company's Official Response

In its formal communication to the stock exchange, Dipna Pharmachem clarified that it possesses no price-sensitive or material information that could result in significant movement of the company's scrip. The company emphasized its commitment to regulatory compliance under applicable SEBI regulations.

Regulatory Compliance Statement

The pharmaceutical company assured that it has made all necessary disclosures under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, within the stipulated time periods. These disclosures cover all information that may have a possible impact or cause fluctuation in the company's stock price.

Managing Director Keyur Dipakkumar Shah, holding DIN 03167258, digitally signed the response, confirming the company's position on the matter. The communication was sent from the company's registered office in Ahmedabad, Gujarat.

Market Volatility Attribution

Dipna Pharmachem specifically noted that currently there are no events, information, or announcements pending that require reporting to the stock exchange. The company attributed the observed price volatility to natural market forces rather than any company-specific developments.

The response concludes that the volatility in the company's stock price on the exchange is purely market-driven, suggesting that external market conditions rather than internal corporate developments are responsible for the price movements that prompted BSE's inquiry.

Dipna Pharmachem Limited , a pharmaceutical trading company, has reported a significant increase in net profit for the first half of the fiscal year 2025-26, despite a decline in total income. The company also raised funds through convertible warrants in September 2025.

Financial Performance Highlights

Dipna Pharmachem Limited's financial results for the six months ended September 30, 2025, show a remarkable improvement in profitability:

The company has managed to significantly improve its bottom line despite a decrease in total income, indicating potential improvements in operational efficiency or cost management.

Fund Raising Through Convertible Warrants

In September 2025, Dipna Pharmachem raised Rs 1,893.31 lakhs through the issuance of convertible warrants. This move may be aimed at strengthening the company's financial position and supporting future growth initiatives.

Utilization of Funds

The company has confirmed that there are no deviations in the utilization of funds from both its rights issue and preferential issue. This transparency is crucial for maintaining investor confidence and ensuring that the raised capital is being used as intended.

Historical Performance Context

To provide a broader perspective on the company's financial trajectory, here's a look at some key metrics from previous fiscal years:

While the company has shown significant growth in revenue since FY2021, there has been a slight decline in the most recent fiscal year. However, the substantial increase in net profit for H1 FY2026 suggests a potential improvement in the company's performance.

Conclusion

Dipna Pharmachem Limited's impressive profit growth in the first half of FY2026, coupled with its fund-raising efforts, may position the company for potential future growth. Investors and market watchers will likely keep a close eye on how the company utilizes its newly raised funds and whether it can maintain its improved profitability in the face of fluctuating revenues.